|
Found 127 result(s) FROM 1963 pages containing the term 'injections'.
Tuesday Apr 27, 2010
Botox May Relieve Pain from Tennis Elbow
Injections of botox helped ease pain but can cause side effects such as reduced strength...
Thursday Apr 22, 2010
Does PRP Therapy Actually Speed Healing?
The controversial blood treatment is gaining popularity amongst athletes, but studies showed mixed results on how effective it is...
Wednesday Nov 18, 2009
FDA Wants Pain Pump Label Warnings
Chondrolysis follows continuous intra-articular local anesthetic infusion, FDA says...
Monday Oct 19, 2009
Denosumab Approval Faces Delay
FDA-watchers predict that the agency will miss the October 19th target set for denosumab approval by as much as 3 months...
Wednesday Sep 30, 2009
FDA Finally OKs Stelara for Psoriasis
The FDA has approved Centocor's Stelara (ustekinumab) for moderate to severe psoriasis...
Monday Aug 31, 2009
Blocking Syndecan-4: A New Way to Treat OA?
Blocking syndecan-4 may represent a whole new approach to treating osteoarthritis...
Thursday Jul 23, 2009
Gene Therapy Cleared in RA Patient Death
The vector used in an RA gene therapy study did not cause the death of a patient who died during the trial...
Monday Jul 13, 2009
I-A Clodronate, HA Try to Beat Placebo for Knee OA
Intra-articular clodronate is as good as hyaluronic acid for knee OA, but placebo might be as good as either...
Tuesday Jun 16, 2009
Golimumab for Psoriatic Arthritis Still Effective at 2 Years
2-Year GO-REVEAL data show durable PsA response to golimumab...
Thursday May 07, 2009
Half of Early RA Patients Treated With Combo DMARDs Have No Disability After 11 Years
Treating early RA with 3 conventional DMARDs leads to more sustained remissions and better outcomes than starting with a single DMARD, regardless of what regimen is used after year 2...
Monday Apr 20, 2009
Forteo May Help Mend Non-Healing Fractures
Subcutaneous daily injections of parathyroid hormone (teriparatide, Forteo, Eli Lilly and Co) may help heal painful non-union or delayed union fractures by stimulating bone stem cells...
Thursday Apr 16, 2009
Once-a-Year Drug Helps Counter Steroid-Linked Bone Loss
A yearly injection of Reclast was found to be more effective at preventing and/or reversing bone loss for patients with asthma or RA than daily bisphosphonate pills…
Thursday Apr 09, 2009
Rituximab May Help Some Severe Lupus Nephritis Cases
Rituximab treatment that achieves early B-cell depletion in cases of severe lupus nephritis can induced complete or partial remission in 60% of patients...
Monday Mar 30, 2009
Hyaluronic Acid Not Useful in Hip OA
A single injection of hyaluronic acid was no better than placebo for hip OA...
Thursday Mar 05, 2009
First Nonsurgical Dupuytren's Rx Likely to Be Auxilium's Xiaflex
Auxilium Pharmaceuticals is requesting expedited approval for Xiaflex™ (clostridial collagenase for injection), a nonsurgical treatment for Dupuytren's contracture...
Wednesday Feb 04, 2009
Anakinra Shows Modest Benefit, Some Risk in RA: Cochrane Review
The IL-1 receptor antagonist Anakinra (Kineret, Amgen) significantly improves rheumatoid arthritis (RA) patients but may be less effective than other biologicals...
Thursday Dec 11, 2008
One-Shot Synvisc Gets FDA Panel OK
An FDA advisory panel has unanimously recommended approval of Genzyme's Synvisc-One™ single-dose hyalin for knee OA pain...
Wednesday Dec 10, 2008
US-Guided Synvisc, Steroids Ease Inoperable Shoulders
Ultrasound-guided hyaluronic acid and steroid offer an alternative for inoperable shoulder impingement syndrome and arthrosynovitis...
Monday Dec 08, 2008
Say Goodbye to Plantar Fasciitis After 15-Minute Treatment
Combining an ultrasound-guided dry needling technique with steroid injection is 95% effective at relieving plantar fasciitis within 3 weeks...
Tuesday Nov 18, 2008
Centocor's Golimumab Gives Durable Skin, Joint Relief in Psoriatic Arthritis, ACR Studies Say
More than half of active psoriatic arthritis patients receiving subcutaneous injections of 50 mg or 100 mg of golimumab (CNTO 148) every 4 weeks showed improvements that lasted through 1 year in the joint and skin symptoms...
Thursday Nov 13, 2008
Parathyroid Hormone Patch May Increase BMD and Adherence
A new patch that delivers parathyroid hormone (PTH) may increase spine and hip BMD and avoid some of the compliance issues seen with subcutaneous daily injections of PTH…
Tuesday Oct 21, 2008
Cutting Better Than Splinting for Carpal Tunnel Pain, Numbness, Weakness
A Cochrane review concludes that surgery is better than splinting for relieving the symptoms of carpal tunnel syndrome, and that a head-to-head comparison of surgery versus steroid injections is needed...
Thursday Oct 09, 2008
Rheumatologists Usually on Target With Intra-Articular Injections, Even Without Ultrasound
New research shows that blind intra-articular injections (IAIs) in rheumatoid arthritis patients, done without ultrasound guidance, are accurate when performed by a trained rheumatologist. Blind injections into the ankle are the most unreliable, at 77% accuracy...
Friday Sep 26, 2008
ASBMR Reports Show 68% Drop in Spinal Fractures With Denosumab, Stronger Effect on Bone Turnover Than With Alendronate, High Patient Preference
Studies reported at the 2008 ASBMR meeting showed that denosumab, which is given twice yearly, was as effective as the best competing agents at preventing osteoporotic fractures. Denosumab produced greater gains in BMD than alendronate and was preferred to once-weekly oral alendronate...
Thursday Sep 25, 2008
Centocor’s Ustekinumab Demonstrates Superior Efficacy to Enbrel® (Etanercept) in Treatment of Moderate-to-Severe Plaque Psoriasis
Greater proportion of patients receiving ustekinumab achieved significant skin clearance versus patients receiving Enbrel...
Tuesday Sep 02, 2008
Logical Therapeutics Reports Positive Results from Phase Ib Clinical Study of Naproxen Prodrug; Dosing Well-Tolerated and Plasma Concentrations Achieve Therapeutic Range
In the phase Ib study twice-daily dosing with LT-NS001 for 7 days resulted in plasma concentrations of naproxen within the therapeutic range, with no serious adverse events reported...
Thursday Aug 21, 2008
Wrinkle Removers, Backed by Science
Scientific evidence has emerged that three anti-aging treatments are clinically effective: topical application of retinol, carbon dioxide resurfacing, and injection of hyaluronic acid…
Wednesday Jul 09, 2008
Lasting Leukemia Risk for AS Patients Treated With Now Banned 224Radium (SpondylAT®)
AS patients who were treated with repeated intravenous injections of 224Radium (SpondylAT®) are at increased risk for developing leukemia…
Tuesday Jun 24, 2008
Steroids Injections May Prevent Rheumatoid Arthrits From Developing
A 3-week course of IM steroids may stop the progression of early rheumatoid arthritis…
Thursday Jun 19, 2008
Baminercept shows good safety, substantial activity against RA in phase II data reported at EULAR
Baminercept alfa, a novel lymphotoxin β-receptor blocker, showed promising safety and efficacy in phase II data reported at EULAR...
Tuesday Jun 17, 2008
At 1 Year, Balloon Kyphoplasty Provides Better Pain, Function Outcomes Than Nonsurgical Care for Osteoporotic Vertebral Fractures
After 12 months, patients with acute vertebral compression fractures treated with balloon kyphoplasty had sustained improvements in pain and function compared with those who received nonsurgical care...
Thursday Jun 12, 2008
Step-Up, Tight Control Abates Early RA in 50% of Patients by 36 Weeks
As many as half of all early rheumatoid arthritis patients may achieve remission within 36 weeks following step-up therapy coupled with tight control...
Monday Jun 09, 2008
Genta Announces Phase I Clinical Trial Results for G4544, an Oral Formulation of Gallium Nitrate, a Novel Potent Drug for Bone Disease
Results from the phase I clinical trial of G4544 showed that the drug was well-tolerated and that blood levels were achieved in a range known to be clinically bioactive...
Monday Jun 02, 2008
Targeted Genetics Reports Positive Interim Findings From Inflammatory Arthritis Phase I/II Trial of tgAAC94; Demonstrates Safety and Preliminary Efficacy, Supports Further Clinical Development
Targeted Genetics Corp's study is designed to assess the safety and potential effect of multiple doses of tgAAC94 administered directly to affected joints of inflammatory arthritis subjects with or without concurrent use of systemic TNF antagonist therapies...
Friday May 23, 2008
Iatrogenic Problems Reported in Low Back Pain, Osteoporosis Patients at AACE Meeting
Cases of iatrogenic Cushing's syndrome (CS) from intra-articular triamcinolone and iatrogenic hypercalcemia from combined teriparatide-hydrochlorothiazide were reported at the American Association of Clinical Endocrinologists 2008 meeting...
Wednesday May 21, 2008
Amgen’s 2nd Phase III Denosumab Osteoporosis Study Meets Primary, Secondary BMD Endpoints in Alendronate Transition Study; Transition Patients Achieved Superior Gains in BMD
Amgen's trial comparing the effects of denosumab vs continued alendronate therapy on bone mineral density demonstrated superior results for primary and all secondary endpoints...
Tuesday May 20, 2008
Drug Works Well for Moderate-to-Severe Psoriasis
Ustekinumab injections are an efficient long-term treatment for moderate-to-severe psoriasis…
Thursday Apr 24, 2008
UCB’s Cimzia® Approved in the US for the Treatment of Moderate-to-Severe Crohn's Disease; Dosed Subcutaneously Every 4 Weeks
The US FDA has approved Cimzia® (certolizumab pegol), indicated for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderate-to-severe active disease who have an inadequate response to conventional therapy...
Wednesday Apr 16, 2008
Lilly’s Forsteo® Receives Approval From European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
Eli Lilly and Co announced that the European Commission has approved a new indication for Forsteo® (teriparatide [rDNA origin] injection) for the treatment of sustained, systemic glucocorticoid-induced osteoporosis (GIOP) in adults at increased risk for fracture...
Tuesday Apr 15, 2008
Pain-Fatigue Link May Explain Why FM, CFS Are More Prevalent in Women
A biological link between pain and fatigue may help explain why more women than men are diagnosed with chronic pain and fatigue conditions like fibromyalgia and chronic fatigue syndrome...
Wednesday Apr 09, 2008
Amgen Phase III Data Show Denosumab, an Inhibitor of RANK Ligand, Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
Amgen announced results from its study in women with early and late stage postmenopausal osteoporosis that show twice-yearly subcutaneous injections of denosumab increased bone mineral density (BMD) at all sites measured...
Tuesday Apr 08, 2008
Testosterone Therapy May Reduce Bone Loss in Older Men
Testosterone injections may improve bone density and prevent osteoporosis in older men with low testosterone levels…
Thursday Mar 13, 2008
Thyroid Hormone Could One Day Treat Osteoporosis
Thyroid stimulating hormone prevented bone loss in experiments with mice and rats...
Thursday Feb 07, 2008
Supplement Shows Promise for Mild Knee Arthritis
A dietary supplement derived from chickens may relieve the pain in patients with mild knee arthritis...
Monday Feb 04, 2008
Amgen, Wyeth Report Enbrel® (etanercept) Significantly Reduced Levels of CRP, a Marker of Inflammation, in Patients with Moderate-to-Severe Plaque Psoriasis
Amgen Inc and Wyeth Pharmaceuticals announced findings from a retrospective analysis demonstrating that Enbrel® (etanercept), a fully human soluble TNF receptor, reduced C-reactive protein (CRP) in patients with moderate-to-severe plaque psoriasis...
Friday Feb 01, 2008
IL-27 Shows Promise for Treating Inflammatory Arthritis
Interleukin-27 (IL-27) can attenuate collagen-induced arthritis when given early in the disease course by blocking Th17 differentiation...
Monday Jan 28, 2008
Amgen Reports Denosumab Osteoporosis Study Met Primary and All Secondary BMD Endpoints in a Direct Comparison With Weekly Alendronate (Fosamax®)
Amgen Inc announced findings from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate in postmenopausal women with low bone mineral density...
Wednesday Jan 23, 2008
Abbott's Humira® Approved in US for Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Abbott Laboratories announced it has received US FDA approval to market Humira® (adalimumab) for adults with moderate-to-severe chronic plaque psoriasis...
Wednesday Jan 16, 2008
Etanercept Clears Plaque Psoriasis in Children and Adolescents
Etanercept (Enbrel®) safely reduces disease severity in children and adolescents with moderate-to-severe plaque psoriasis, and improvements are evident as early as the second week of therapy...
Tuesday Dec 18, 2007
Rigel's Oral Syk Kinase Inhibitor, R788 (tamatinib fosdium), Achieves Statistically Significant ACR-20, -50, -70 in Phase II RA Clinical Study; Achieves Effect As Early As 1 Week
Rigel Pharmaceuticals, Inc announced that its oral syk kinase inhibitor, R788 (tamatinib fosdium), has demonstrated statistically significant results in treating rheumatoid arthritis patients in a recently completed phase II clinical trial...
Friday Dec 14, 2007
Acologix Reports AC-100 Promotes Articular Surface Restoration and Subchondral Bone Healing in Osteochondral Defect Study in Goats
Acologix, Inc announced preclinical study results demonstrating that AC-100 (Dentonin®) promoted cartilage regeneration in an animal model. Dentonin is a synthetic peptide derived from an endogenous human protein produced by bone and dental cells...
Wednesday Dec 12, 2007
Ferring's Euflexxaâ„¢ (1% sodium hyaluronate) is Effective in Treating Knee OA and Reduces Pain that Interferes with ADLs; Shows Equal Effectiveness in Disease Stages Two and Three
Ferring Pharmaceuticals announced the results of two clinical studies on the efficacy of Euflexxaâ„¢, an intra-articular hyaluronic acid (IA-HA) for the relief of pain in knee osteoarthritis (OA)...
Thursday Dec 06, 2007
IM Vitamin D Provides Little Fracture Protection in Relatively Healthy, Community-Dwelling Elderly
If fracture risk in the elderly is associated with low vitamin D levels, why doesn't an annual vitamin D injection reduce fracture rates?...
Thursday Nov 29, 2007
Osiris Announces Clinically and Statistically Significant 1-Year Data From Phase I/II Trial of Chondrogenâ„¢; OA Knee Patients Receive Single Injection of Adult Stem Cells Into Knee
Osiris Therapeutics, Inc, a leading stem cell therapeutic company, announced positive 1-year interim results in the evaluation of Chondrogenâ„¢, a preparation of mesenchymal stem cells obtained from the bone marrow of healthy adult donors and formulated for direct injection into the knee...
Monday Nov 19, 2007
Early Surgery Trumps Steroids for Long-Term Outcomes in Carpal Tunnel Syndrome
Decompression surgery is three times more effective than local corticosteroid injections for primary carpal syndrome...
Tuesday Nov 13, 2007
Single Botulinum Toxin Injection Smooths Out OA Shoulder Pain
A single intra-articular injection of botulinum toxin type A relieved shoulder pain for a month in patients with refractory OA...
Tuesday Nov 13, 2007
Anti-IL-12/23 Monoclonal Produces Dramatic Results in Psoriatic Arthritis
The anti-IL-12/23 monoclonal antibody ustekinumab produced dramatic, durable improvements in psoriatic arthritis, according to phase II data reported at the American College of Rheumatology...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Improved Articular, Skin, and Nail Manifestations in Patients With Psoriatic Arthritis in Phase III Study; Met Primary and Major Secondary Endpoints
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that patients with active psoriatic arthritis (PsA) receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase III biologic study (GO-REVEAL trial) in PsA subjects...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of AS in Phase III Study; Monthly Treatment Yielded Marked Improvements in Physical Function
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that more than half of patients receiving monthly subcutaneous injections of golimumab 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis (AS), according to the phase III study (GO-RAISE trial) results...
Monday Sep 24, 2007
Risk of Infection in TNF-Inhibitor Treatment May Be Higher Than Thought
A new analysis of data from the British Society for Rheumatology Biologics Register suggests that the risk of serious infection is increased during certain phases of TNF-inhibitor treatment...
Thursday Aug 02, 2007
FDA Stops Arthritis Gene Therapy Trial After Patient Dies
CIAOMed takes an in-depth look into what went wrong in the inflammatory arthritis gene therapy trial that resulted in a patient's death and what this incident may mean for the future of gene trials, particularly in arthritis...
Wednesday Jul 25, 2007
Targeted Genetics' Inflammatory Arthritis Phase I/II Trial Placed on Clinical Hold
Targeted Genetics Corp, a clinical-stage biotechnology company, announced that after recent discussions with the US FDA, the phase I/II clinical study of tgAAC94, an investigational therapy for the treatment of inflammatory arthritis, has been placed on clinical hold.
Wednesday Jul 11, 2007
Genzyme's Pivotal Trial of Hylastan for OA of the Knee Fails to Achieve Primary Endpoint
Genzyme Corp announced unfavorable topline results from a pivotal study investigating the safety and efficacy of hylastan, a viscosupplementation product, in treating pain in patients with osteoarthritis (OA) of the knee...
Tuesday Jul 03, 2007
Conventional Drugs Can Beat Back Early RA
Two-year data show that intensive treatment with methotrexate (MTX) and intra-articular corticosteroid can reduce X-ray progression in early RA...
Tuesday Jun 26, 2007
Cytos Reports Results From Phase I/IIa Study With Vaccine Candidate CYT007-TNFQb for Treatment of Psoriasis; Demonstrated Safety and Tolerability but Transient Efficacy
Cytos Biotechnology AG, a public biotechnology company that specializes in the discovery, development, and commercialization of a new class of biopharmaceutical products called Immunodrugsâ„¢ reported results from a multicenter, randomized, placebo-controlled, and double-blind combined phase I/IIa study with CYT007-TNFQb, a novel therapeutic vaccine candidate for the treatment of psoriasis and other inflammatory conditions including rheumatoid arthritis (RA)...
Tuesday Jun 19, 2007
Single Dose of Denosumab Reduces Bone Erosion in RA
MRI and X-ray data show that a single dose of denosumab reduces progression of bone erosions in RA patients...
Friday Jun 15, 2007
Two Thirds of Gout Patients Receiving No, or Not Enough Treatment
A number of new treatment options for gout are available, but the major clinical problem is that even after gout diagnosis, only about one third of patients receive urate-lowering therapy...
Monday Jun 11, 2007
Abbott's HUMIRA® (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott Laboratories announced that it has received marketing authorization from the European Commission for the use of Humira® (adalimumab) as a treatment for severe Crohn's disease (CD)...
Friday May 25, 2007
Accumulating Evidence Supports Adalimumab for Severe Psoriatic Arthritis
Adalimumab (Humira®) is safe and effective for patients with active psoriatic arthritis (PsA) who showed an inadequate response to disease-modifying antirheumatic drugs (DMARDs)...
Thursday May 24, 2007
Single Local Corticosteroid Injection Is the Most Effective Way to Avoid Surgery in Severe Carpal Tunnel Syndrome
An updated review of 12 studies comprising 671 patients found that local corticosteroid injections can provide at least a month of relief for patients with severe carpal tunnel syndrome...
Tuesday May 15, 2007
TNF-α, IL-1 Mediate Postmenopausal Osteoporosis
Blocking TNF-α or IL-1 can slow postmenopausal bone loss...
Thursday Apr 19, 2007
Little High-Quality Evidence Found for Either Diagnosis or Treatment of Septic Arthritis
A systematic review of research on septic arthritis finds little reliable evidence to guide either diagnosis or management. The review identifies antibiotic choice, route of administration, and duration as key unanswered questions, as well as whether closed aspiration or open arthroscopy/arthrotomy is better for cleaning out an infected joint...
Monday Mar 05, 2007
AAN Therapeutics Panel Discourages Use of Epidural Steroid Injections for Radicular Low Back or Cervical Pain
The American Academy of Neurology's therapeutics and technology assessment subcommittee cautions against use of epidural steroid injections for radicular lumbosacral pain and concludes that there is insufficient evidence to make any recommendation for radicular cervical pain...
Thursday Feb 22, 2007
Study Supports Intra-Articular Steroid Injections for Hip OA
Steroid injections in the hip to treat hip OA were effective in an uncontrolled pilot study and should be studied in randomized, controlled trials...
Thursday Feb 08, 2007
More Patient Input on Design Needed If RA Patients Are Actually to Wear Therapeutic Shoes
More attention to shape and design of shoes for feet of RA patients...
Thursday Feb 08, 2007
Centocor Releases Phase II Data on CNTO 1275, a Monoclonal Antibody Targeting IL-12/IL-23, for Chronic Plaque Psoriasis
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that phase II data showed that patients with moderate-to-severe plaque psoriasis who received subcutaneous injections of CNTO 1275 experienced significant clearance of skin disease and significant improvements in quality of life...
Friday Jan 12, 2007
Lavage With Steroids Better Than Aspiration With Steroids for Inflammatory Knee Arthritis
Arthroscopic lavage plus steroids provides a more prolonged therapeutic benefit than joint aspiration plus steroids or lavage alone in knee inflammatory arthritis...
Thursday Jan 11, 2007
Combination DMARD Therapy Leads to Sustained Remission in RA
Treating rheumatoid arthritis (RA) with a combination of disease modifying antirheumatic drugs (DMARDs) plus prednisolone results in sustained remission and blocks the progression of radiographic joint damage in a "remarkable proportion" of patients...
Monday Dec 18, 2006
Genzyme, Anika Retain Separate Medicare Code and Reimbursement Rate for Synvisc and Orthovisc, Respectively; Centers for Medicare and Medicaid Services Reverse Earlier Decision
Genzyme Corp (CAMBRIDGE, Massachusetts) and Anika Therapeutics, Inc (WOBURN, Massachusetts) independently announced that Synvisc® (hylan G-F 20) and Orthovisc®, their respective hyaluronic acid (HA) viscosupplement products used to treat pain caused by osteoarthritis (OA) of the knee, will maintain separate reimbursement codes and rates for 2007, according to a decision made by the Centers for Medicare and Medicaid Services (CMS).
Tuesday Dec 05, 2006
Nastech, P&G Amend Agreement for Development of Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis
Nastech Pharmaceutical Company Inc (BOTHELL, Washington) announced the amendment of its previous agreement with Procter & Gamble Pharmaceuticals, Inc (P&G) for the clinical development program of the parathyroid hormone (PTH1-34) nasal spray for the treatment of osteoporosis. The amendment includes an additional phase II dose ranging study as well as a change in the timing of payments.
Thursday Nov 30, 2006
Low Risk of Jaw Osteonecrosis Seen With Bisphosphonates for Osteoporosis
Osteonecrosis of the jaw has emerged as an unanticipated problem associated with bisphosphonate treatment in cancer patients, but is seldom a significant risk at the doses used for osteoporosis...
Thursday Nov 16, 2006
Anti-TNF-α Golimumab (CNTO 148), Under Development by Centocor and Schering-Plough, Provides Sustained Improvement in Moderately-to-Severely Active Rheumatoid Arthritis in Phase II Study
Centocor, Inc (HORSHAM, Pennsylvania), a wholly owned subsidiary of Johnson & Johnson, announced that 1-year data, presented at the 70th Annual Meeting of the American College of Rheumatology in Washington, DC, showed that nearly 75% of patients with moderately-to-severely active rheumatoid arthritis (RA) receiving golimumab (CNTO 148) and methotrexate experienced at least 20% improvement in arthritis symptoms (ACR 20) at week 52.
Wednesday Nov 01, 2006
Genzyme to Challenge Medicare Code and Reimbursement Decision for Synvisc
Genzyme Corporation, one of the world's leading biotechnology companies, announced that it will work with the Centers for Medicare and Medicaid Services (CMS), government officials and, if necessary, through legal channels to dispute a CMS decision to group all viscosupplementation products into a single reimbursement code.
Wednesday Oct 25, 2006
NSAIDs/DMARDs Can Thwart Antibiotic-Refractory Lyme Arthritis
Report highlights effective postantibiotic strategies for treating antibiotic-refractory Lyme arthritis and identifies risk factors for the rare but vexing condition... Steere AC, Angelis SM. Arthritis Rheum. 2006;54:3079-3086
Thursday Oct 05, 2006
Little Gained From Combining Etanercept and Sulfasalazine in RA
Patients whose RA is active despite treatment with sulfasalazine benefit from switching to etanercept, but combining the two drugs provides little additional benefit... Combe B, et al. Ann Rheum Dis. 2006;65:1357-1362.
Tuesday Oct 03, 2006
Genzyme's Synvisc Receives European Approval to Expand Label to Include the Treatment of OA Pain of the Ankle and Shoulder
Genzyme Corporation announced that it has received European approval to expand the CE mark labeling for SynviscR (hylan G-F 20) to include treatment of pain due to osteoarthritis (OA) of the ankle and shoulder. Genzyme expects to begin marketing Synvisc in the EU with its new label immediately.
Wednesday Aug 23, 2006
Genzyme Files for European Approval to Expand Label for Synvisc in Ankle and Shoulder Indications
Genzyme Corp. announced that it has filed with the European authority to expand the continuing education mark for Synvisc® (hylan G-F 20) to include treatment of pain due to osteoarthritis (OA) of the ankle and shoulder...
Monday Aug 14, 2006
TissueGene Initiates Phase I Study of TissueGene-C in Patients With Degenerative Joint Disease of the Knee Prior to Total Knee Arthroplasty
TissueGene, Inc. announced the initiation of a phase I clinical trial of the company's cell-mediated therapy, TissueGene-C (TG-C).
Tuesday Jul 18, 2006
Protalex Raises $15.2 Million to Advance PRTX-100 in Phase II for Idiopathic Thrombocytopenic Purpura
Protalex, Inc, announced that it has raised approximately $15.2 million in gross proceeds in a private placement. Investors participating in this transaction include LBI Group Inc, vSpring Capital, CIDC Inc, Emerging Technology Partners, and additional selected institutional and accredited private investors.
Saturday Jul 08, 2006
New Study Supports Steroid Injections for Hip OA
Data from a new randomized, controlled trial support the EULAR recommendation on steroid injections for hip OA....Lambert RG, et al. EULAR 2006.
Tuesday Jun 20, 2006
Nastech Receives $7 Million Milestone Payment From P&G; Will Make and Supply to P&G PTH1-34 Nasal Spray for Osteoporosis
Nastech Pharmaceutical Company Inc, of Bothell, Washington, announced the receipt of a $7 million payment for attaining a development milestone under its development and commercialization agreement with Procter & Gamble Pharmaceuticals, Inc, pertaining to parathyroid hormone (PTH1-34) nasal spray for the treatment of osteoporosis...
Wednesday Jun 14, 2006
Arthritis Gene Therapy Inches Forward
TNF inhibitors and other biologicals may command more attention, and stem cells may be more controversial, but arthritis gene therapy continues to move quietly ahead... Evans C, et al. Arthritis Rheum. 2006;54:1714-1729.
Monday Jun 05, 2006
PsA Enthesopathy As Cause of Plantar Fasciitis Responds to TNF Inhibitors
The TNF inhibitors infliximab and etanercept are both effective for the treatment of enthesopathy associated with psoriatic arthritis... Ritchlin CT. J Rheumatol. 15 May 2006; [Epub ahead of print]
Thursday May 25, 2006
Hyperosmolar Dextrose Sweetens Chronic Tendinosis
Ultrasound-guided hyperosmolar dextrose injections into tendon relieve chronic tendinosis... Maxwell NJ, Ryan M, Taunton JE, Wong A. Presented at: American Roentgen Ray Society 106th Annual Meeting; April 30–May 5; Vancouver, BC. Abstract 172.
Monday May 22, 2006
MTX Plus Steroid Injection Into Joints Helps Control Early RA
Combining MTX with intraarticular steroids provides prompt control of early RA... Hetland ML, et al. Arthritis Rheum. 2006;54:1401-1409.
Wednesday May 17, 2006
Argos Licenses sCD83 Autoimmune Disorder Treatment Rights From Beckman Coulter
Argos Therapeutics, of Durham, NC, announced that Beckman Coulter, of Fullerton, California, has granted Argos an exclusive license for therapeutic use of the soluble protein CD83 (sCD83) for autoimmune disorders and transplant rejection...
Friday May 12, 2006
Cochrane Review Questions Muscle Relaxants, NSAIDs, Botox for Neck Pain
A Cochrane systematic review of randomized trials of medicines and injections used to treat mechanical neck disorders such as whiplash found scant support for commonly used treatments such as muscle relaxants and NSAIDs, and a general lack of solid clinical research on treatment of neck pain... Peloso PM, et al. J Rheumatol. 2006;33:957-967.
Monday May 01, 2006
Nastech's Intranasal Parathyroid Hormone (PTH1-34) Demonstrates Similar Pharmacokinetic Profile to Approved Injectable Product, ForteoR (Teriparatide)
Nastech Pharmaceutical Company Inc, of Bothell, Washington, reported pharmacokinetic data from a phase I study of parathyroid hormone (PTH1-34) nasal spray demonstrating a similar pharmacokinetic profile to the approved subcutaneous product, Forteo®...
Monday Apr 17, 2006
Subcutaneous Infliximab Shows Promise in Treating RA
An experimental subcutaneous and intramuscular formulation of the tumor necrosis factor-alpha inhibitor infliximab is well tolerated and associated with a favorable American College of Rheumatology (ACR) response…Westhovens R, et al. J Rheumatol. 2006;33:5. First release April 1, 2006.
Thursday Mar 30, 2006
Sodium Hyaluronate Effective in Chronic Shoulder Pain
Injections of sodium hyaluronate may be an effective and safe alternative to cyclooxygenase-2 inhibitors and other nonsteroidal anti-inflammatory drugs for the treatment of chronic shoulder pain... Blaine TA, et al. Presented at: 73rd Annual Meeting of the American Academy of Orthopaedic Surgeons; March 22–26, 2006; Chicago, Ill. Abstract 426.
Monday Mar 20, 2006
Single Injection of GDF-5 May Repair Degenerated Discs
A single injection of recombinant human growth and differentiation factor (GDF-5) may induce recovery of intravertebral disc height... Presented at: 52nd Annual Meeting of the Orthopaedic Research Society; March 18–22, 2006; Chicago, Ill. Abstract 14.
Monday Mar 13, 2006
Steroids Not Beneficial for Genital Ulcers in Behçet's Syndrome
Low-dose depot corticosteroids do not have a beneficial effect on the genital ulcers of Behçet's syndrome, but they may help control erythema nodosum lesions—especially in females... Mat C, et al. Rheumatology. 2006;45:348-352.
Tuesday Mar 07, 2006
High, Prolonged Inflammatory Activity in Rheumatoid Arthritis Increases Lymphoma Risk
The severity of disease, not its treatments, is a risk factor for the development of malignant lymphomas in rheumatoid arthritis patients... Baecklund E, et al. Arthritis Rheum. 2006;54:692-701.
Thursday Mar 02, 2006
Denosumab Shows Promise in Phase II Study of Bone Mineral Density
Twice yearly injections of denosumab (previously known as AMG 162) significantly increased bone mineral density in the total hip, lumbar spine, distal 1/3 radius, and total body of postmenopausal women compared with placebo... McClung MR, et al. N Engl J Med. 2006;354:821-831.
Wednesday Mar 01, 2006
Effects of IV Steroids for Treatment of Acute Sciatica Are Transient
Intravenous steroids reduce pain in patients with severe acute discogenic sciatica, although the improvement is small and transient... Finckh A, et al. Spine. 2006;31:377-381.
Tuesday Jan 10, 2006
ARMADA Trial Supports Long-Term Safety and Efficacy of Adalimumab and Background Methotrexate for RA
Adalimumab plus background methotrexate is a safe and well-tolerated combination that has demonstrated a sustained clinical response and remission in patients with active rheumatoid arthritis (RA) for up to 4 years... Weinblatt ME, et al. Ann Rheum Dis. Published online Dec. 16, 2005; doi:10.1136/ard.2005.044404.
Tuesday Dec 20, 2005
Radius Acquires Ipsen's Parathyroid Hormone–Related Protein Analog for Osteoporosis
Radius (Cambridge, Mass) has acquired from Ipsen the exclusive worldwide rights (excluding Japan) to the drug BA058...
Sunday Dec 18, 2005
Etanercept May Be Effective for the Depression and Fatigue of Psoriasis
A new phase III trial has found that the tumor necrosis factor-alpha (TNF-α) inhibitor etanercept not only improves the clinical manifestations of psoriasis but also relieves the fatigue and depression associated with the disease. The findings point to the role higher concentrations of proinflammatory cytokines such as TNF-α have in major depressive symptoms…. Tyring S, et al. Lancet [serial online]. December 15, 2005.
Wednesday Nov 16, 2005
TNF-α Antagonist Adalimumab Shows Promise in AS
Encouraging results from the ATLAS trial suggest that adalimumab and other TNF-α inhibitors may be effective in reducing the signs and symptoms of ankylosing spondylitis... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Wednesday Nov 16, 2005
Amgen's Denosumab Effective in Increasing Bone Mineral Density in Postmenopausal Patients
Amgen has announced that twice-yearly subcutaneous injections of 60 mg denosumab increased bone mineral density (BMD) of the lumbar spine by 7.4% and of the total hip by 5.1% compared with 6.2% and 3.4%, respectively, for alendronate (Fosamax®) 70 mg/week over a 24-month period.
Monday Oct 31, 2005
Meta-Analysis Points to the Need to Customize Treatment for Subtypes of Juvenile Idiopathic Arthritis
With the increased recognition that radiologic joint and cartilage damage occurs earlier in the course of juvenile idiopathic arthritis than originally thought, a recently released literature review underlines the importance of taking a customized approach to treatment of the disease. However, despite treatment advances, researchers argue that there is no evidence-based consensus on the optimal treatment regimen for several subtypes of JIA. Hashkes PJ, Laxer RM. JAMA. 2005;294:1671-1684.
Monday Oct 24, 2005
Endogenous Opioids May Not Be Effective in Chronic Pain
Activating endogenous opioids may not be an effective way to treat chronic pain, according to an experimental study in male rats with chronic- and acute-induced arthritis. Li Z, et al. Arthritis Rheum. 2005;52:3210-3219.
Wednesday Oct 12, 2005
Nastech Reports Positive Phase I Data for Intranasal PTH 1-34 for Osteoporosis
Nastech Pharmaceutical Company Inc, of Bothell, Washington, a leader in molecular biology-based drug delivery technologies, announced...
Thursday Oct 06, 2005
New Study Results Suggest That Two Courses of Parathyroid Hormone May Reduce Fracture Risk in Patients with Severe Osteoporosis
Osteoporosis patients who remain at high risk for fracture despite a course of parathyroid hormone (PTH) therapy may benefit from a second discrete course of PTH . . . Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research; September 23–27, 2005; Nashville, Tenn. Presentation 1079.
Tuesday Jul 26, 2005
Systemic Lupus Erythematosus: Is There a Phthalate Connection?
Murine studies suggest that exposure to phthalates may increase susceptibility to SLE and possibly other autoimmune disorders... Lim S-Y and Ghosh SK. J Autoimmun. 2005;25:33-45
Wednesday Jun 29, 2005
The Immune Response Corporation Identifies Reduced FOXP3 Levels in MS Patients
An ongoing clinical trial conducted by The Immune Response Corporation (IRC) of Carlsbad, California, and Oregon Health & Science University (OHSU) in Portland has demonstrated that the investigational T-cell receptor (TCR) peptide vaccine NeuroVaxTM significantly increases levels of FOXP3, a transcription factor necessary for regulatory T-cell (Treg cells) development.
Tuesday Jun 28, 2005
Botox Injections Improve Symptoms in Patients With Raynaud's Phenomenon
Injections of botulinum toxin type A may accelerate the rewarming process by inhibiting vasoconstriction in patients with secondary Raynaud's phenomenon... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Friday Apr 22, 2005
High-Dose Methotrexate Particularly Effective for Polyarticular Juvenile Rheumatoid Arthritis
A head-to-head trial comparing leflunomide and methotrexate monotherapy showed that both drugs demonstrated significant improvement in ACR Pediatric 30 responses through a 48-week course of therapy...Silverman E, et al. New Engl J Med. 2005;352:1655-1666.
Friday Apr 15, 2005
Small Interfering RNA Suppresses Inflammation in Mouse Model of Arthritis
Local administratipon of TNF-α-directed siRNA inhibits collagen-induced arthritis in mice, suggesting a potential treatment strategy for RA...Schiffelers, RM. Arthritis Rheum. 2005;52:1314-1318.
Friday Apr 01, 2005
Injectable Capsaicin Formulation Safe and Effective in Knee Osteoarthritis Patients
In the search for alternatives to coxibs, traditional nonsteroidal anti-inflammatory drugs, and opioid analgesics, preliminary data suggest that injectable capsaicin is safe and well tolerated in patients with osteoarthritic knee pain, without the side effects of systemic treatments...Presented at: 24th Annual Scientific Meeting of the American Pain Society; March 30-April 2, 2005; Boston, Mass.
Monday Mar 14, 2005
Hyaluronate Injection Improves Function of Arthritic Ankle
Investigator-initiated pilot study indicates that sodium hyaluronate provides sustained relief of pain and improved function in patients suffering from osteoarthritis of the ankle...72nd Annual Meeting of the American Academy of Orthopaedic Surgeons; February 23-27, 2005; Washington, DC.
Saturday Mar 12, 2005
Genzyme Acquires a Second-Generation Cartilage Repair Product; Buys Back Rights to SynviscR
Genzyme Corp has acquired Verigen AG, a private German company that has developed a proprietary cell-therapy product for cartilage repair.
Wednesday Oct 20, 2004
New Phase III Trial With Abatacept Gives Hope to Methotrexate Nonresponders
A phase III clinical trial reported that nearly half of rheumatoid arthritis patients receiving monthly injections of the T-cell inactivator abatacept achieved at least a 50% reduction in symptoms... Kremer J, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Texas.
Monday Oct 04, 2004
FDA Approves Etanercept as Pre-Filled Syringe, Infliximab as First-Line Therapy for Moderate to Severe RA
The FDA has approved etanercept (Enbrel) as a pre-filled syringe formulation for once weekly use, and granted approval for a supplemental labeling change stating that the medication can induce a major clinical response in patients with rheumatoid arthritis (RA). In another regulatory decision, the FDA has approved the use of infliximab (Remicade) in combination with methotrexate as a first-line treatment for patients with RA.
Monday Sep 20, 2004
Image-Guided Needle Placement's Contribution to Outcomes Questioned
Although image guidance improves the accuracy of needle placement, the practice has not been proven to improve outcomes. (Hall S, Buchbinder R. Ann Rheum Dis. 2004;63:1007-1008.)
Wednesday Jul 14, 2004
Mycobacterial Vaccine Less Effective than Immunotherapies in Treatment of PSA
Friday Jun 11, 2004
Pain Management Remains a Key Component to Treatment of Inflammatory Conditions
Understanding the mechanisms involved in chronic pain and treating it as effectively as possible is a crucial component to the management of rheumatoid arthritis and other inflammatory disease...
|
